Meet the Author – MaryBeth Pfeiffer – Townhall – tomorrow
Join us for a live webinar with MaryBeth Pfeiffer as she discusses the article she wrote about hydroxychloroquine and ivermectin for early covid, and the…
Ablaze Pharmaceuticals Launches with $75 Million Series A to Bring Novel Targeted Radiopharmaceuticals to the Greater China Market
Shanghai and San Diego-based Ablaze Pharmaceuticals, a clinical-stage company focused on the development and commercialization of innovative targeted radiopharmaceutical therapies (TRT) against tumor targets, announced…
Adagio Therapeutics Reports SARS-CoV-2 Antibody, ADG20, Currently in Phase 2/3 Trials, Has in vitro Activity Against Omicron Variant
Adagio Therapeutics announced an update on its lead SARS-CoV-2 monoclonal antibody, ADG20. ADG20 was designed to provide broad and potent neutralizing activity against SARS-CoV-2, including…
NicOx Reports Positive Post Hoc Results from Sub-Group Treated with NCX 4251 in Phase 2b Mississippi Trial for Dry Eye Disease
NixOx announced positive post hoc results from a subgroup of patients in the Phase 2b Mississippi clinical trial. Analysis for this subgroup of patients, who…
MEI Pharma and Kyowa Kirin Announce Interim Data from Phase 2 TIDAL Study Evaluating Single Agent Zandelisib for Relapsed or Refractory Follicular Lymphoma
MEI Pharma and Kyowa Kirin announced results from the ongoing Phase 2 TIDAL study evaluating zandelisib as a single agent for follicular lymphoma (FL) patients…
IMV Announces First Patient Dosed in Phase 1b Clinical Study Evaluating its Lead Compound in Patients with Breast Cancer
IMV Inc. (NASDAQ: IMV; TSX: IMV), a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX platform to treat solid and…